PACS (PACS)
Market Price (8/28/2026): $44.29 | Market Cap: $7.0 BilSector: Health Care | Industry: Health Care Facilities
PACS (PACS)
Market Price (8/28/2026): $44.29Market Cap: $7.0 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10% Megatrend and thematic driversMegatrends include Healthcare Real Estate. Themes include Post-Acute Care Real Estate. | Weak multi-year price returns2Y Excs Rtn is -28% | Stock price has recently run up significantly12M Rtn12 month market price return is 273% High stock price volatilityVol 12M is 102% Short seller reportHindenburg Research report on 11/4/2024. Key risksPACS key risks include [1] potential NYSE delisting stemming from its failure to timely file financial reports and a necessary accounting restatement, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10% |
| Megatrend and thematic driversMegatrends include Healthcare Real Estate. Themes include Post-Acute Care Real Estate. |
| Weak multi-year price returns2Y Excs Rtn is -28% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 273% |
| High stock price volatilityVol 12M is 102% |
| Short seller reportHindenburg Research report on 11/4/2024. |
| Key risksPACS key risks include [1] potential NYSE delisting stemming from its failure to timely file financial reports and a necessary accounting restatement, Show more. |
Qualitative Assessment
AI Analysis | Feedback
PACS (PACS) stock has gained about 30% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Earnings Beat.
PACS reported robust financial results for fiscal Q1 2026 (ended March 31, 2026), announcing an adjusted Earnings Per Share (EPS) of $0.50, which surpassed analyst expectations of $0.44. Revenue also demonstrated strength, growing 11% year-over-year to $1.42 billion.
2. Exceptional Fiscal Q2 2026 Financial Performance.
The company continued its strong performance into fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst projections. PACS reported an adjusted EPS of $0.63, beating consensus estimates of $0.54 by $0.09. Revenue reached $1.43 billion, surpassing analyst estimates of $1.41 billion. This quarter saw net income increase by 49.8% year-over-year to $76.3 million and Adjusted EBITDA grow by 24.6% to $166.8 million.
Show more
PACS (PACS) stock has gained about 30% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Earnings Beat.
PACS reported robust financial results for fiscal Q1 2026 (ended March 31, 2026), announcing an adjusted Earnings Per Share (EPS) of $0.50, which surpassed analyst expectations of $0.44. Revenue also demonstrated strength, growing 11% year-over-year to $1.42 billion.
2. Exceptional Fiscal Q2 2026 Financial Performance.
The company continued its strong performance into fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst projections. PACS reported an adjusted EPS of $0.63, beating consensus estimates of $0.54 by $0.09. Revenue reached $1.43 billion, surpassing analyst estimates of $1.41 billion. This quarter saw net income increase by 49.8% year-over-year to $76.3 million and Adjusted EBITDA grow by 24.6% to $166.8 million.
3. Increased Full-Year 2026 Guidance.
Following the strong fiscal Q2 2026 results, PACS raised its full-year 2026 Adjusted EBITDA guidance to a range of $640 million to $660 million, an increase from its prior range of $605 million to $625 million. The company also boosted its revenue guidance for the full year to $5.75 billion to $5.85 billion, up from $5.65 billion to $5.75 billion.
4. Strategic Acquisitions and High Occupancy Rates.
PACS expanded its operational footprint by closing on the acquisition of 20 of 22 Texas facilities from Eduro Healthcare by August 1, 2026, with the remaining facilities expected to close in fiscal Q3 and Q4 2026. The company also maintained strong occupancy levels across its portfolio, with overall occupancy at 90.4% in fiscal Q2 2026, considerably above the industry average of 79.5%. Same-store skilled nursing facility (SNF) revenue increased by 5.8%, with same-store SNF occupancy improving to 90.6%.
5. Positive Analyst Sentiment and Price Target Increases.
Multiple Wall Street analysts responded positively to PACS's performance, issuing upgrades and increasing their price targets for the stock. Firms such as Oppenheimer, Truist, RBC, and UBS raised their price targets, with some reaching as high as $62.00. The consensus rating for PACS remains a "Moderate Buy" or "Strong Buy" with an average price target ranging from $56.00 to $59.20.
Show less
Stock Movement Drivers
Fundamental Drivers
The 31.9% change in PACS stock from 4/30/2026 to 8/27/2026 was primarily driven by a 33.9% change in the company's Net Income Margin (%).| (LTM values as of) | 4302026 | 8272026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.55 | 44.24 | 31.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,289 | 5,551 | 5.0% |
| Net Income Margin (%) | 3.6% | 4.8% | 33.9% |
| P/E Multiple | 27.4 | 26.0 | -5.3% |
| Shares Outstanding (Mil) | 157 | 158 | -0.9% |
| Cumulative Contribution | 31.9% |
Market Drivers
4/30/2026 to 8/27/2026| Return | Correlation | |
|---|---|---|
| PACS | 31.9% | |
| Market (SPY) | 7.3% | 8.9% |
| Sector (XLV) | 17.5% | 23.3% |
Fundamental Drivers
The 31.0% change in PACS stock from 1/31/2026 to 8/27/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 8272026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.76 | 44.24 | 31.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 5,551 | 0.0% |
| Net Income Margin (%) | � | 4.8% | 0.0% |
| P/E Multiple | � | 26.0 | 0.0% |
| Shares Outstanding (Mil) | 129 | 158 | -18.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/27/2026| Return | Correlation | |
|---|---|---|
| PACS | 31.0% | |
| Market (SPY) | 11.7% | 20.0% |
| Sector (XLV) | 11.3% | 20.1% |
Fundamental Drivers
The 300.0% change in PACS stock from 7/31/2025 to 8/27/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 8272026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.06 | 44.24 | 300.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 5,551 | 0.0% |
| Net Income Margin (%) | � | 4.8% | 0.0% |
| P/E Multiple | � | 26.0 | 0.0% |
| Shares Outstanding (Mil) | 214 | 158 | 35.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/27/2026| Return | Correlation | |
|---|---|---|
| PACS | 300.0% | |
| Market (SPY) | 23.0% | 5.9% |
| Sector (XLV) | 33.3% | 10.3% |
Fundamental Drivers
nullnull
Market Drivers
7/31/2023 to 8/27/2026| Return | Correlation | |
|---|---|---|
| PACS | ||
| Market (SPY) | 74.4% | 13.9% |
| Sector (XLV) | 33.9% | 18.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PACS Return | - | - | - | -43% | 193% | 16% | 93% |
| Peers Return | 12% | -15% | 64% | 8% | 59% | 27% | 245% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| PACS Win Rate | - | - | - | 67% | 58% | 62% | |
| Peers Win Rate | 50% | 47% | 64% | 53% | 67% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PACS Max Drawdown | - | - | - | - | -47% | -28% | |
| Peers Max Drawdown | -31% | -36% | -20% | -25% | -18% | -24% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ENSG, BKD, NHC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/27/2026 (YTD)
How Low Can It Go
| Event | PACS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.8% | -18.8% |
| % Gain to Breakeven | 53.4% | 23.1% |
| Time to Breakeven | 58 days | 79 days |
In The Past
PACS's stock fell -34.8% during the 2025 US Tariff Shock. Such a loss loss requires a 53.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PACS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.8% | -18.8% |
| % Gain to Breakeven | 53.4% | 23.1% |
| Time to Breakeven | 58 days | 79 days |
In The Past
PACS's stock fell -34.8% during the 2025 US Tariff Shock. Such a loss loss requires a 53.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About PACS (PACS)
PACS is a leading post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of over 200 independently operated facilities across nine U.S. states. The company specializes in short-term transitional care for patients recuperating from acute conditions, illnesses, or serious medical procedures after hospital discharge, though it also provides long-term custodial care, senior care, assisted living, and independent living options. PACS's significant growth is driven by its expertise in acquiring underperforming long-term custodial care facilities and transforming them into higher acuity, high value-add transitional care centers by investing in clinical teams, technology, and operational enhancements.
The company operates through a decentralized model, empowering local leaders at each facility to make clinical and operational decisions autonomously. These local teams receive comprehensive central support from "PACS Services," which provides a robust suite of technology, administrative, financial, human resources, legal, and risk management services, enabling facilities to focus on patient care and regulatory compliance. PACS's primary customers are individuals aged 65 and older, with a substantial portion of its revenue generated from payments by third-party payors, particularly Medicare and Medicaid. This model has led to strong performance, with an average 4.1 CMS Quality Measures Star rating and 93% occupancy rate for mature facilities, exceeding industry averages.
AI Analysis | Feedback
PACS is like a Marriott or Hilton for skilled nursing facilities, operating a large network of decentralized care centers with central support.
AI Analysis | Feedback
- Skilled Nursing Care: Providing specialized medical and rehabilitative services for patients requiring 24-hour in-patient services, including short-term transitional care after hospital discharge and long-term custodial care.
- Assisted Living: Offering residential care and support for seniors who need assistance with daily activities.
- Independent Living: Providing housing and a community environment for self-sufficient seniors.
AI Analysis | Feedback
PACS primarily sells its services to individuals (patients and residents) in need of post-acute and senior care. The company serves the following categories of customers:
- Individuals requiring Short-Term Transitional Skilled Nursing Care: These are patients who have been discharged from hospitals but still require 24-hour in-patient services to recuperate from acute conditions, illnesses, or serious medical procedures. This is the company's primary focus and a growing segment of their business.
- Individuals requiring Long-Term Custodial Skilled Nursing Care: While PACS's strategy is to transform facilities into higher acuity short-term care, they also serve individuals who need extended skilled nursing services for chronic conditions or ongoing care.
- Seniors and Individuals seeking Assisted Living and Independent Living: In some of its communities, PACS provides senior care, assisted living, and independent living options for individuals who need varying levels of support, from minimal assistance to more comprehensive daily living aid, but typically not requiring the same intensity of medical care as skilled nursing patients.
AI Analysis | Feedback
AI Analysis | Feedback
Jason Murray, Co-Founder, CEO and Chairman
Jason Murray is the Co-Founder, CEO, and Chairman of PACS Group, Inc., which he co-founded with Mark Hancock in 2013. He has over 20 years of experience as an executive in acute and post-acute healthcare settings and is a licensed nursing home administrator. Before co-founding PACS, he worked as a healthcare executive and licensed nursing home administrator. Murray holds a master's degree in healthcare administration and was named 2023 Mountain West Entrepreneur of the Year by Ernst & Young.
Mark Hancock, Co-Founder, Executive Vice Chairman, and Interim Chief Financial Officer
Mark Hancock is a Co-Founder, Executive Vice Chairman, and Interim Chief Financial Officer of PACS Group, Inc. He co-founded the company with Jason Murray in 2013 and previously served as CFO from January 2013 until January 2024, when he was appointed Executive Vice Chairman. He was re-appointed interim CFO on September 3, 2025, following the resignation of the previous CFO. Hancock has over 20 years of experience as a finance professional. Prior to co-founding PACS, he worked as Vice President of Finance and Treasurer of Farm Credit Mid-America, a nursing home administrator at a facility affiliated with Plum Healthcare Group, Director of Corporate Finance for Steel Technologies Inc., and a Finance Manager for Ford Motor Company. He was also named a 2023 Mountain West Entrepreneur of the Year by Ernst & Young.
Josh Jergensen, President and Chief Operating Officer
Josh Jergensen is the President and Chief Operating Officer at PACS Group, Inc. He has been providing operational support to all facilities within the PACS portfolio since 2014. Jergensen is a licensed nursing home administrator and an approved preceptor in California, with more than 10 years of experience operating complex multi-story skilled nursing facilities.
John Mitchell, Chief Legal Officer and Secretary
John Mitchell serves as the Chief Legal Officer and Secretary for PACS Group, Inc., managing the company's legal department. He joined PACS in 2017. Previously, he held positions as Vice President, Legal at HCP, a NYSE-traded healthcare-focused real estate investment trust, and as Senior Vice President, Legal, and Chief Compliance Officer at Skilled Healthcare Group, a NYSE-traded skilled nursing company. He began his career at an international law firm with a focus on corporate, finance, and mergers and acquisitions.
Michelle Lewis, Executive Vice President, Chief Accounting Officer
Michelle Lewis has served as PACS Group, Inc.'s Executive Vice President, Chief Accounting Officer since January 2023. She joined the company in July 2018 and held various roles of increasing responsibility, including Controller. Before joining PACS, Ms. Lewis owned and operated her own certified public accounting firm and provided controller functions at a privately held healthcare organization.
AI Analysis | Feedback
The key risks to PACS's business are:
-
High Dependence on Government Reimbursement Programs and Regulatory Compliance: A substantial portion of PACS's revenue is generated from payments from third-party payors, particularly Medicare and Medicaid, which together accounted for 76.2% of their routine revenue in 2023 and 77.8% of total revenue in 2022. The company operates in a highly regulated industry with stringent compliance obligations, and any changes to these government reimbursement programs or failure to comply with applicable laws and regulations could result in significant expenditures, regulatory penalties, and a material adverse effect on their financial performance and operations.
-
Acquisition and Integration Strategy Risks: PACS's significant historical growth has been primarily driven by its strategy of acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care facilities. The success of this strategy relies on their expertise in identifying suitable acquisition targets, investing in clinical teams and processes, and upgrading various aspects of the business, often involving an up to three-year post-acquisition transition period. Failure to successfully execute this acquisition and integration strategy, or to effectively convert facilities to higher-value care models, could impede their growth, operational improvements, and profitability.
AI Analysis | Feedback
AI Analysis | Feedback
The primary addressable market for PACS is the Skilled Nursing Facility (SNF) industry in the U.S. The Centers for Medicare & Medicaid Services (CMS) expects total industry expenditures for SNFs to increase from $193.6 billion in 2022 to $283.3 billion in 2031.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for PACS
- Strategic Acquisitions and Facility Transformation: PACS's historical growth has been primarily driven by its strategy of acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care facilities. This involves investing in clinical teams and processes, upgrading technology, and improving overall operations, which is expected to continue driving revenue growth as new facilities are integrated and optimized.
- Improved Occupancy Rates and Skilled Mix: The company's operational model focuses on implementing best practices in acquired facilities, leading to significant improvements in clinical quality, occupancy rates, and skilled mix by nursing patient days (the percentage of Medicare and managed care patients). As new facilities mature and existing ones continue to optimize, these enhanced metrics are expected to contribute to increased revenue per patient day and overall revenue growth.
- Overall Expansion of the Skilled Nursing Facility (SNF) Industry: PACS operates within a growing market, with the Centers for Medicare & Medicaid Services (CMS) projecting total SNF industry expenditures to increase at a compound annual growth rate (CAGR) of 4.3% from $193.6 billion in 2022 to $283.3 billion in 2031. As one of the largest SNF operators in the United States, PACS is well-positioned to benefit from this broader industry expansion.
- Geographic Expansion: PACS anticipates further penetrating its reach into its current nine states and entering new states in the future through available acquisition opportunities. This geographic expansion will increase its total number of facilities and patient base, contributing to sustained revenue growth.
AI Analysis | Feedback
Outbound Investments
- PACS has historically grown primarily through a disciplined acquisition strategy, identifying and acquiring underperforming long-term custodial care skilled nursing facilities.
- The company focuses on converting acquired facilities into higher-value short-term transitional care facilities by investing in clinical teams, processes, technology, equipment, training, staffing, and aesthetics.
- PACS intends to explore additional purchases of real-estate assets, through purchase options or right-of-first refusals in existing leases, as well as acquisitions and de novo construction of purpose-built facilities.
Capital Expenditures
- The primary focus of capital expenditures is on implementing best practices in acquired facilities, including investments in clinical teams and processes, and upgrading technology, equipment, training, staffing, and aesthetics.
- These expenditures aim to realize and sustain the full potential of facilities during an up to three-year post-acquisition transition period.
Peer Outperformance in Health Care Facilities
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 11.4% | 82.6% | 133.3% | CAH 407% · MCK 354% · COR 182% |
| Health Care Services | 20 | 19.8% | 45.0% | 3.4% | HIMS 310% · RDNT 142% · DGX 81% |
| Managed Health Care | 8 | 33.7% | -2.9% | 2.5% | OSCR 114% · HQY 42% · ELV 15% |
| Health Care Facilities ← | 24 | 4.6% | -4.2% | -16.8% | THC 257% · NHC 244% · ENSG 113% |
| Health Care Equipment | 51 | -5.4% | -6.4% | -21.4% | POCI 10975% · UFPT 336% · GKOS 220% |
| Health Care Supplies | 12 | 33.7% | -14.8% | -34.4% | LNTH 291% · HAE 71% · MMSI 25% |
| Pharmaceuticals | 63 | -0.6% | 9.6% | -37.0% | LQDA 2490% · INDV 1235% · ETON 1136% |
| Life Sciences Tools & Services | 108 | -1.2% | -31.2% | -72.1% | SNWV 1802% · MEDP 239% · AXGN 208% |
| Health Care Technology | 21 | -22.7% | -56.6% | -74.4% | SPOK 119% · HSTM -1% · VEEV -15% |
| Biotechnology | 365 | 8.8% | -24.8% | -77.7% | BRTX 102900% · DNTH 1685% · CELZ 1529% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Where Does PACS Stock Rank Among Competitors? | 02/24/2026 | |
| PACS Stock Surges 132%, With A 7-Day Winning Spree | 12/02/2025 | |
| PACS Stock Rockets 123% With 6-Day Winning Streak | 11/27/2025 | |
| PACS Stock On Fire: Up 120% With 5-Day Winning Streak | 11/26/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 108.89 |
| Mkt Cap | 5.2 |
| Rev LTM | 4,269 |
| Op Inc LTM | 278 |
| FCF LTM | 134 |
| FCF 3Y Avg | 94 |
| CFO LTM | 399 |
| CFO 3Y Avg | 287 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.0% |
| Rev Chg 3Y Avg | 13.0% |
| Rev Chg Q | 9.0% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Inc Chg LTM | 53.8% |
| Op Inc Chg 3Y Avg | 66.2% |
| Op Mgn LTM | 8.0% |
| Op Mgn 3Y Avg | 6.5% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 10.7% |
| CFO/Rev 3Y Avg | 8.7% |
| FCF/Rev LTM | 3.2% |
| FCF/Rev 3Y Avg | 2.6% |
Price Behavior
| Market Price | $44.24 | |
| Market Cap ($ Bil) | 6.9 | |
| First Trading Date | 04/11/2024 | |
| Distance from 52W High | -8.7% | |
| 50 Days | 200 Days | |
| DMA Price | $43.36 | $36.68 |
| DMA Trend | up | up |
| Distance from DMA | 2.0% | 20.6% |
| 3M | 1YR | |
| Volatility | 41.8% | 102.2% |
| Downside Capture | 37.38 | -51.66 |
| Upside Capture | 104.61 | 112.30 |
| Correlation (SPY) | 13.7% | 5.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.44 | 0.54 | 0.48 | 0.95 | 0.48 | 0.14 |
| Up Beta | -0.68 | -1.06 | -0.03 | 1.32 | 1.94 | -0.25 |
| Down Beta | 0.41 | 1.31 | 2.70 | 1.78 | -0.05 | -0.71 |
| Up Capture | 137% | 157% | 63% | 85% | 122% | 34% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 13 | 24 | 32 | 61 | 126 | 281 |
| Down Capture | 18% | -3% | -106% | 35% | -107% | 74% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 9 | 19 | 31 | 65 | 125 | 290 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 281.4% | 102.0% | 1.71 | - |
| Sector ETF (XLV) | 26.9% | 16.0% | 1.30 | 9.8% |
| Equity (SPY) | 20.6% | 12.8% | 1.19 | 5.5% |
| Gold (GLD) | 35.6% | 28.8% | 1.05 | 0.8% |
| Commodities (DBC) | 40.3% | 20.3% | 1.55 | -11.4% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 11.7% |
| Bitcoin (BTCUSD) | -29.7% | 43.6% | -0.69 | -6.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 15.0% | 82.4% | 0.70 | - |
| Sector ETF (XLV) | 6.5% | 15.1% | 0.24 | 18.5% |
| Equity (SPY) | 13.4% | 17.2% | 0.60 | 13.8% |
| Gold (GLD) | 20.5% | 18.7% | 0.89 | 1.9% |
| Commodities (DBC) | 11.0% | 19.6% | 0.44 | -3.2% |
| Real Estate (VNQ) | 2.2% | 18.9% | 0.01 | 21.7% |
| Bitcoin (BTCUSD) | 11.0% | 52.7% | 0.39 | -0.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 7.2% | 82.4% | 0.70 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 18.5% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 13.8% |
| Gold (GLD) | 12.6% | 16.3% | 0.64 | 1.9% |
| Commodities (DBC) | 7.5% | 18.1% | 0.33 | -3.2% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 21.7% |
| Bitcoin (BTCUSD) | 63.6% | 66.1% | 1.03 | -0.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 8/13/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 1.9% | 0.3% | |
| 5/11/2026 | 28.6% | 15.4% | 7.6% |
| 2/26/2026 | -12.4% | -14.6% | -26.6% |
| 11/19/2025 | 55.3% | 91.1% | 119.1% |
| 9/11/2025 | 24.5% | 45.5% | 69.9% |
| 11/6/2024 | -38.8% | -30.5% | -50.5% |
| 8/12/2024 | 18.8% | 23.1% | 22.2% |
| 5/13/2024 | 7.3% | 13.8% | 17.8% |
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 5 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 21.7% | 19.2% | 22.2% |
| Median Negative | -25.6% | -22.6% | -38.5% |
| Max Positive | 55.3% | 91.1% | 119.1% |
| Max Negative | -38.8% | -30.5% | -50.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 1.9% | 0.3% | |
| 5/11/2026 | 28.6% | 15.4% | 7.6% |
| 2/26/2026 | -12.4% | -14.6% | -26.6% |
| 11/19/2025 | 55.3% | 91.1% | 119.1% |
| 9/11/2025 | 24.5% | 45.5% | 69.9% |
| 11/6/2024 | -38.8% | -30.5% | -50.5% |
| 8/12/2024 | 18.8% | 23.1% | 22.2% |
| 5/13/2024 | 7.3% | 13.8% | 17.8% |
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 5 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 21.7% | 19.2% | 22.2% |
| Median Negative | -25.6% | -22.6% | -38.5% |
| Max Positive | 55.3% | 91.1% | 119.1% |
| Max Negative | -38.8% | -30.5% | -50.5% |
Recent Forward Guidance
Updated 8/5/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 5.75 Bil | 5.80 Bil | 5.85 Bil | Raised | Guidance: 5.70 Bil for 2026 | ||
| 2026 Adjusted EBITDA | 640.00 Mil | 650.00 Mil | 660.00 Mil | Raised | Guidance: 615.00 Mil for 2026 | ||
Prior: Q1 2026 Earnings Reported 5/11/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted EBITDA | 605.00 Mil | 615.00 Mil | 625.00 Mil | 8.8% | Raised | Guidance: 565.00 Mil for 2026 | |
| 2026 Revenue | 5.65 Bil | 5.70 Bil | 5.75 Bil | 0 | Affirmed | Guidance: 5.70 Bil for 2026 | |
Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 5.65 Bil | 5.70 Bil | 5.75 Bil | 7.5% | Higher New | Guidance: 5.30 Bil for 2025 | |
| 2026 Adjusted EBITDA | 555.00 Mil | 565.00 Mil | 575.00 Mil | 16.5% | Higher New | Guidance: 485.00 Mil for 2025 | |
Insider Activity
Updated 8/27/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Conway, Patrick Hugh | Direct | Sell | 8272026 | 44.41 | 3,497 | 155,302 | 397,336 | Form | |
| 2 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8242026 | 43.90 | 59,244 | 2,601,086 | 2,401,357,754 | Form |
| 3 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8242026 | 43.92 | 91,306 | 4,010,347 | 2,404,912,894 | Form |
| 4 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8192026 | 44.26 | 84,717 | 3,749,995 | 2,427,730,191 | Form |
| 5 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8192026 | 44.18 | 66,797 | 2,951,138 | 2,426,851,727 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Conway, Patrick Hugh | Direct | Sell | 8272026 | 44.41 | 3,497 | 155,302 | 397,336 | Form | |
| 2 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8242026 | 43.90 | 59,244 | 2,601,086 | 2,401,357,754 | Form |
| 3 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8242026 | 43.92 | 91,306 | 4,010,347 | 2,404,912,894 | Form |
| 4 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8192026 | 44.26 | 84,717 | 3,749,995 | 2,427,730,191 | Form |
| 5 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8192026 | 44.18 | 66,797 | 2,951,138 | 2,426,851,727 | Form |
| 6 | Murray, Jason Hulse | Co-Founder, CEO & Chairman | Direct | Sell | 8192026 | 44.16 | 84,602 | 3,736,301 | 2,428,844,387 | Form |
| 7 | Jergensen, Joshua | President & COO | Direct | Sell | 8142026 | 45.59 | 40,000 | 1,823,689 | 115,636,490 | Form |
| 8 | Hancock, Mark | Direct | Sell | 7162026 | 45.05 | 3,332 | 150,115 | 2,428,639,891 | Form | |
| 9 | Jergensen, Joshua | President & COO | Direct | Sell | 7162026 | 45.02 | 40,000 | 1,800,718 | 115,980,626 | Form |
| 10 | Hancock, Mark | Direct | Sell | 7162026 | 45.03 | 10,296 | 463,680 | 2,427,846,578 | Form | |
| 11 | Hancock, Mark | Direct | Sell | 7102026 | 45.06 | 4,966 | 223,781 | 2,429,803,856 | Form | |
| 12 | Hancock, Mark | Direct | Sell | 7102026 | 45.07 | 20,338 | 916,611 | 2,430,361,975 | Form | |
| 13 | Lewis, Michelle Renee | Chief Accounting Officer | Direct | Sell | 7062026 | 45.04 | 4,137 | 186,333 | 16,004,637 | Form |
| 14 | Hancock, Mark | Direct | Sell | 7062026 | 45.33 | 142,163 | 6,444,860 | 2,445,595,806 | Form | |
| 15 | Lewis, Michelle Renee | Chief Accounting Officer | Direct | Sell | 7062026 | 45.03 | 6,663 | 300,032 | 16,187,015 | Form |
| 16 | Hancock, Mark | Direct | Sell | 7062026 | 45.01 | 12,825 | 577,290 | 2,434,656,790 | Form | |
| 17 | Lewis, Michelle Renee | Chief Accounting Officer | Direct | Sell | 7062026 | 45.01 | 4,200 | 189,059 | 16,481,373 | Form |
| 18 | Hancock, Mark | Direct | Sell | 7062026 | 45.02 | 6,080 | 273,716 | 2,435,569,505 | Form | |
| 19 | Hancock, Mark | Co Fndr; Exec V Chair | Direct | Sell | 6262026 | 40.50 | 61,931 | 2,508,085 | 2,191,050,145 | Form |
| 20 | Hancock, Mark | Co Fndr; Exec V Chair | Direct | Sell | 6262026 | 40.33 | 138,069 | 5,567,701 | 2,184,211,674 | Form |
| 21 | Lewis, Michelle Renee | Chief Accounting Officer | Direct | Sell | 6262026 | 40.01 | 15,000 | 600,178 | 14,817,927 | Form |
| 22 | Hancock, Mark | Co Fndr; Exec V Chair | Direct | Sell | 6222026 | 35.31 | 63,680 | 2,248,415 | 1,917,317,697 | Form |
| 23 | Hancock, Mark | Co Fndr; Exec V Chair | Direct | Sell | 6172026 | 35.90 | 83,066 | 2,982,385 | 1,951,955,936 | Form |
| 24 | Hancock, Mark | Co Fndr; Exec V Chair | Direct | Sell | 6172026 | 36.34 | 153,254 | 5,568,756 | 1,978,513,308 | Form |
| 25 | Mitchell, John Todd | Chief Legal Officer & Sec. | Direct | Sell | 5192026 | 37.16 | 27,389 | 1,017,692 | 29,858,080 | Form |
| 26 | Mitchell, John Todd | Chief Legal Officer & Sec. | Direct | Sell | 5192026 | 38.02 | 52,763 | 2,006,014 | 31,592,353 | Form |
| 27 | Jergensen, Joshua | President & COO | Direct | Sell | 3172026 | 34.28 | 36,335 | 1,245,647 | 91,442,790 | Form |
| 28 | Dilsaver, Evelyn S | Direct | Buy | 11262025 | 29.90 | 16,724 | 499,997 | 679,828 | Form | |
| 29 | Mitchell, John Todd | Chief Legal Officer & Sec. | Direct | Sell | 11262025 | 29.89 | 159,556 | 4,768,379 | 22,588,386 | Form |
Investor Activity (13F)
Updated Aug 28, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.